Cesca Therapeutics Submits Investigational Device Exemption

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Cesca Therapeutics Submits Investigational Device Exemption Supplement for SurgWerks™ CLI Pivotal Trial

RANCHO CORDOVA, Calif., June 01, 2016 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc . (NASDAQ: KOOL ), an autologous cell-based regenerative medicine company, today announced that the Company has submitted an Investigational Device Exemption (IDE) Supplement to the U.S. Food and Drug Administration (FDA) for its previously approved pivotal trial for the treatment of patients with critical limb ischemia (CLI), using the Company’s SurgWerks TM system. The Company expects the FDA to submit its response to the IDE supplement within 30 days of submission.

After careful review of both current literature and data available from earlier studies, and in conjunction with expert independent advisors, the Company concluded that Amputation-Free Survival (AFS) would not be a practical primary endpoint for a successful pivotal trial. Limb revascularization procedures are not specifically intended to improve survival and, as a result, endpoints that couple limb-related outcomes with all-cause mortality over time (such as Amputation Free Survival) are inherently compromised as specific measures of the effectiveness of revascularization. The Company concluded that adequately powering a study using AFS as the primary endpoint would be prohibitively time consuming and costly and that adequate statistical power could only be practically generated if data was produced from every treated limb.

Alternative endpoints considered included (i) Clinically Meaningful Endpoints such as Complete Wound/Ulcer Healing and the 6 Minute Walk Test, (ii) Patient Reported Outcome Measures such as Rest Pain and Quality of Life, and (iii) Surrogate Endpoints such as Ankle Brachial Index, Toe Brachial Index, Transcutaneous Oxygen Pressure, Hyperspectral Imaging, Skin Perfusion Pressure and Blood Oxygenation Level dependent MRI.

In the supplement, the Company proposed Transcutaneous Oxygen Pressure (TcPO2) as a surrogate endpoint. TcPO2 is a non-invasive, clinically-accepted method for measuring the amount of oxygen diffused from capillaries through the skin, and reflects both the oxygen supply and the metabolic demand in a specific region. The Company believes that ample clinical evidence exists to support the claim that (i) TcPO2 predicts the risk of major amputation, (ii) endovascular interventions, including cell therapy, increase (improve) TcPO2 values, and (iii) cell therapy significantly reduces the risk of major amputation.

The revised Phase III trial design will focus on the mean difference in TcPO2 measured at 12 months between a treatment arm and a control arm. The general design of the study will include 3:1 randomization, a 12 month follow-up program, and Rutherford category 5 CLI patients. The estimated sample size needed to successfully demonstrate safety and a statistically powered efficacy result is 148 patients (100 patients in the treatment arm, 33 patients in the control arm with a further 10% assumed to cover dropouts).

The supplement also details changes to the protocol that are expected to improve both patient enrollment and study flow. These include expanding the cohort to include both “no option” and “poor option” CLI patients, removing unnecessary patient testing requirements, improving the mapping and injection procedure, and eliminating the Blinded Independent Review Committee for enrollment and endpoint analysis. The supplement also expands the number of secondary endpoints and extends the follow-up period beyond an observational phase to facilitate collection of additional data in support of reimbursement from The Centers for Medicare and Medicaid Services (CMS).

“We believe that the submission of this IDE supplement for our pivotal trial for the treatment of CLI patients with SurgWerks TM is highly significant,” said Robin Stracey, Cesca’s Chief Executive Officer. “The change in primary endpoint and the proposed amendments to the protocol dramatically improve the probability of a successful outcome compared to past trial designs. The historical reliance on AFS as a clinical endpoint has prohibited new regenerative technologies from having an achievable pathway to regulatory approval. If cell or gene-based therapies are to be available to US physicians, an alternative endpoint has to be used for establishing efficacy. We look forward to working with the FDA throughout the review process and will continue to provide updates in the coming weeks.”

About Cesca Therapeutics Inc. Cesca Therapeutics Inc. ( www.cescatherapeutics.com ) is engaged in the research, development, and commercialization of cellular therapies and delivery systems for use in regenerative medicine. The Company is a leader in the development and manufacture of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapeutics. These include:

  • T h e SurgWerks™ System (in development) - a proprietary system comprised of the SurgWerks Processing  Platform,  including  devices  and  analytics,  and  indication-specific  SurgWerks Procedure Kits for use in regenerative stem cell therapy at the point-of-care for vascular and orthopedic diseases.
  • T h e CellWerks™ System (in development) - a proprietary cell processing system with associated analytics for intra-laboratory preparation of adult stem cells from bone marrow or blood.
  • T h e AutoXpress® System (AXP®) - a proprietary automated device and companion sterile disposable for concentrating hematopoietic stem cells from cord blood.
  • T h e MarrowXpress™ System (MXP™) - a derivative product of the AXP and its accompanying sterile disposable for the isolation and concentration of hematopoietic stem cells from bone marrow.
  • T h e BioArchive® System - an automated cryogenic device used by cord blood banks for the cryopreservation and storage of cord blood stem cell concentrate for future use.
  • M anual bag sets for use in the processing and cryogenic storage of cord blood.

Forward-Looking Statements and Safe Harbor Statement under the Private Securities Litigation  Reform Act of 1995 This press release includes statements of future expectations and other forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current views and assumptions, speak only as of the date hereof and are subject to change.  Forward-looking statements can often be identified by words such as “may,” “could,” “potential,” “continue,” and similar expressions and include, but are not limited to, statements regarding research and product commercialization. These forward-looking statements are not guarantees of future results and are subject to known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially and adversely from those expressed or implied in such statements. A more complete description of risks that could cause actual events to differ from the outcomes predicted by these forward-looking statements is set forth under the caption "Risk Factors" in our Annual Report on Form 10-K, in our Quarterly Reports on Form 10-Q, and in other reports filed with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.  We undertake no obligation to revise or update publicly any forward-looking statements for any reason, except as required by law.

Company Contact: Cesca Therapeutics Inc. ir@cescatherapeutics.com Investor Contact: The Ruth Group Lee Roth / Tram Bui 646-536-7012 / 7035 lroth@theruthgroup.com / tbui@theruthgroup.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Youdao Profit Holds, but Revenue and Cash Raise Flags

Updated Category News Views 70

Profitability Arrived With a Few Splinters A shrinking top line wearing a profit badge is never an easy thing to applaud. Youdao delivered RMB1.4 billion in third-quarter 2026 revenue, or US$213.1 million, down 12.3% from a year earlier. Yet income from operations climbed 19.2% to RMB33.7 million, making this the company’s ninth consecutive quarter of operating...

Continue Reading
Five Films Put Modern Infrastructure Under a Lens

Updated Category News Views 121

Most infrastructure only earns a thought when it breaks, and that is precisely the nerve these films are trying to touch. Nicely Done Productions has released the final five installments of its ten-part Threads of Connectivity documentary series, hosted on National Geographic's global digital platform. The subjects are illycaffè, Cargill, Honeywell Aerospace, Western...

Continue Reading
FLX Opens a New Door to Pre-IPO Deal Flow for Advisors

Updated Category News Views 160

Private-market chatter has been leaking past the velvet rope for years, and advisors are sick of learning about it after a client already has a pitch deck in hand. FLX Networks is responding to that irritation by letting its eligible advisor and wealth-management members review select pre-IPO opportunities shared by other members. Announced November 19, 2026, the move is...

Continue Reading
Botanica’s Illuminations Carries More Than Holiday Glow

Updated Category News Views 29

Two million lights are doing more than brightening up a few winter evenings in Wichita. Illuminations at Botanica returns from November 23, 2026, through January 2, 2027, and the pleasant part of this story is that the spectacle has a practical backbone: it is Botanica’s largest fundraiser. For a garden nonprofit, that matters a whole lot more than another shiny...

Continue Reading
Why Professional Collaboration May Matter More in AI

Updated Category News Views 33

Three smart professionals can still hand a client a mess when nobody owns the handoff. That unglamorous reality sits behind the Professional Collaboration Institute, or PCI, which Sarano and Brooke Kelley plan to launch in a virtual briefing on December 2. The outfit wants to turn cross-profession coordination into a teachable, measurable discipline rather than leave it...

Continue Reading
AT&T's Dec. 8 UBS Chat Puts Stankey's Updates on Watch

Updated Category News Views 98

A Small Slot With a Big Audience A calendar entry can still matter when the man holding the microphone runs AT&T. John Stankey, AT&T chairman and chief executive, is scheduled for a fireside chat at the UBS Global Media and Communications Conference on Tuesday, Dec. 8, beginning at 8:15 a.m. Eastern time. The company says the event will be webcast live through its...

Continue Reading
Pennsylvania Rebate Rules Matter Before Year-End Filing

Updated Category News Views 105

A missed rebate form can sting harder than most people expect, especially when a household has already spent the year watching property taxes, rent, groceries, and every other stubborn bill chew through fixed income. Pennsylvania’s Property Tax/Rent Rebate Program is not glamorous, and it is certainly not an investing story. It is, however, the kind of direct household...

Continue Reading
Africa’s Digital Ownership Debate Gets More Serious

Updated Category News Views 70

Ownership was the uncomfortable word hanging over Cape Town on day two of Africa Tech Festival 2026, and frankly it should make investors sit up. Africa’s digital economy has no shortage of big promises, shiny AI demos or overseas executives talking about opportunity. The harder question is who funds the pipes, owns the data, makes the rules and actually keeps the...

Continue Reading
Lowe's Dec. 9 Conference Puts Strategy on the Clock

Updated Category News Views 95

A Calendar Entry With Real Weight December 9 is not earnings day, but it is the sort of date shareholders ought to circle anyway. Lowe's plans to hold its 2026 Analyst and Investor Conference at 8 a.m. Eastern time in New York City, with a live webcast available for those not sitting in the room. For owners of NYSE:LOW, these gatherings can be more useful than the usual...

Continue Reading
Zoomlion’s Australian Service Push Looks Built to Last

Updated Category News Views 163

Five Australian business centres are one thing; getting a stalled crane or earthmover moving again is the whole ballgame. Zoomlion’s Nov. 4 customer gathering in Sydney matters because Chairman and CEO Zhan Chunxin kept the discussion on the unglamorous stuff: product quality, technical support, parts availability and local training. That is exactly where an equipment...

Continue Reading

Top 5 Most Recently Viewed Articles

Unlocking Digital Services for 627 Million People Worldwide

Updated Category News Views 94

Harnessing Digital Opportunities for the Excluded Population In an era where digital connectivity is vital for success, a significant portion of the global population remains disconnected. This is not just a statistic but a call to action as we face the reality that over 627 million people worldwide are still excluded from essential digital services. This number surpasses...

Continue Reading
Game-Changing Investment in Cancer Treatment by First Ascent Biomedical

Updated Category News Views 105

Revolutionary Investment in Cancer Treatment First Ascent Biomedical, celebrated for its advanced approach to personalized cancer therapy, has recently secured an impressive $6 million investment from Vidal Duart Enterprises, Inc. This funding marks a significant stride for the company as it aims to reshape the landscape of medical oncology. Accompanying this investment,...

Continue Reading
Ameris Bancorp Plans Q3 2024 Earnings Announcement Soon

Updated Category News Views 63

Ameris Bancorp Set to Reveal Third Quarter Earnings Ameris Bancorp, a notable financial institution with a significant presence in the Southeast, has announced its plans to release third quarter 2024 earnings. The company will share its financial results via a press release following the market close on a Thursday, in late October. This strategic timing aligns with the...

Continue Reading
Key Leadership Change at Amerant Bank Enhances Credit Oversight

Updated Category News Views 226

Amerant Bank Welcomes Jeffrey K. Tischler Amerant Bank, known for its strong reputation in the banking sector, has announced a significant addition to its executive team. Jeffrey K. Tischler has been appointed as the Senior Executive Vice President and Chief Credit Officer. This crucial role involves overseeing the bank's Credit Services, Portfolio Management, and Credit...

Continue Reading
Modera South Shore Begins Preleasing: Modern Living Awaits

Updated Category News Views 229

Modera South Shore: A New Era of Living Modera South Shore is set to transform contemporary living with the addition of 270 stylish homes to a friendly community. Nestled in a charming seaside setting, this modern garden-style community is positioned ideally for those seeking a balanced lifestyle. With a thoughtful design aimed at both comfort and elegance, it promises to...

Continue Reading